Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | CRHBP | P24387 | 2/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512687 | 0.78 | ITGB2 (0.46) | OXTRMAOAMAOBABCG2ITGB2 | |
| SCHEMBL11926932 | 0.71 | MAPT (0.37) | GAASMN1; SMN2HTTKMT2ANPC1 | |
| SCHEMBL9116482 | 0.70 | MAOA (0.37) | OXTRMAOAMAOBABCG2ITGB2 | |
| SCHEMBL10170816 | 0.69 | OXTR (0.52) | OXTRMAOAMAOBABCG2ITGB2 | |
| SCHEMBL30349594 | 0.69 | — | — | |
| SCHEMBL346944 | 0.69 | — | — | |
| SCHEMBL29965099 | 0.68 | — | — | |
| SCHEMBL7332054 | 0.68 | — | — | |
| SCHEMBL121521 | 0.68 | — | — | |
| Bromide SCHEMBL22498666 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | claimed |
| EP-3421454-B1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-04-05 | — | — | EP | claimed |
| US-10851079-B2 | Piperidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-12-01 | — | — | US | claimed |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-07 | — | — | US | claimed |
| EP-3421454-A1 | PIPERIDINE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2019-01-02 | — | — | EP | claimed |
| WO-2000035916-A1 | HERBICIDAL 4-BENZOYLISOXAZOLES | AVENTIS CROPSCIENCE S.A. (FR) | 2000-06-22 | — | — | WO | claimed |
| US-6048984-A | HERBICIDES AND ANTIGROWTH AGENTS | RHONE-POULENC AGRICULTURE LIMITED (GB) | 2000-04-11 | — | — | US | claimed |
| US-5977376-A | Herbicidal 2-benzoylcyclohexane-1,3-diones and related compounds | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1999-11-02 | — | — | US | claimed |
| EP-0918056-A1 | Herbicides | RHONE-POULENC AGRICULTURE LTD. (GB) | 1999-05-26 | — | — | EP | claimed |
| WO-1999003845-A1 | 2-BENZOYLCYCLOHEXANE-1,3-DIONE DERIVATIVES AS HERBICIDES AND INTERMEDIATES | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1999-01-28 | — | — | WO | claimed |
| EP-0156224-B1 | NOVEL BENZOXATHIIN DERIVATIVE, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION | SUNTORY LIMITED (JP) | 1990-11-28 | — | — | EP | claimed |
| EP-0156224-A2 | Novel benzoxathiin derivative, process for preparing them and pharmaceutical composition | SUNTORY LIMITED (JP) | 1985-10-02 | — | — | EP | claimed |
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-13 | — | — | US | disclosed |
| CN-113795498-B | Organic compound and organic electroluminescent element comprising same | 材料科学有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240286999-A1 | AZABICYCLO[3.1.0]HEXANE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-0379979-A1 | Pyrazolopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-01 | — | — | EP | disclosed |
| EP-0156224-A2 | Novel benzoxathiin derivative, process for preparing them and pharmaceutical composition | SUNTORY LIMITED (JP) | 1985-10-02 | — | — | EP | disclosed |
| EP-0156224-A2 | Novel benzoxathiin derivative, process for preparing them and pharmaceutical composition | SUNTORY LIMITED (JP) | 1985-10-02 | — | — | EP | disclosed |
| EP-0156224-A2 | Novel benzoxathiin derivative, process for preparing them and pharmaceutical composition | SUNTORY LIMITED (JP) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240286999-A1 | AZABICYCLO[3.1.0]HEXANE COMPOUND | MALT1, CXCR1, AZI2 | OXTR 2194/4885MAOA 928/4885MAOB 324/4885 |
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | OXTR 23/4885MAOA 549/4885MAOB 557/4885 |
| US-10851079-B2 | Piperidine derivative | EP300, SLC11A2, TBC1D5 | OXTR 4123/4885MAOA 2662/4885MAOB 2500/4885 |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | OXTR 415/4885MAOA 910/4885MAOB 746/4885 |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | EP300, SLC11A2, TBC1D5 | OXTR 4123/4885MAOA 2662/4885MAOB 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.